semaglutide fda submission Approves Oral as First GLP-1 Pill for Weight Loss Semaglutide shortage ends as FDA
Description
The global GLP-1 market is estimated to grow from USD 49.3 billion in the current year to USD 157

Discover how combining HRT and GLP-1 therapy helps women in perimenopause and menopause achieve better weight loss, improved metabolic health, and long-term wellness

This review also covers the chemistry behind SNAC and toxicity as well as mechanisms to enhance the oral delivery of clinically proven molecules like simaglutide and other small molecules under clinical development, as well as other permeation enhancers for efficient delivery of proteins and peptides.

DNF-10 yeast peptides have been shown to help reduce cravings and quiet the food talk
Selina Wang reports on Medicares $50 GLP-1 weight-loss drug program, while Heidi Skolnik breaks down long-term benefits, risks and how patients should approach use of the medications.

Weight Loss Tirzepatide: -21.5% vs Semaglutide: -14.5% Substantial divergence with implications for long-term outcomes